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The challenge of infectious 
the European perspective 
Experts in infectious diseases, clinical niicrobiology and 
public health from 17 European countries gathered in 
Amsterdam on 18-19 December 1996 for the 
international conference ‘The challenge of infectious 
disease, the European perspective’, organized by the 
Health Research Promotion Programme of The 
Netherlands. The objective was to discuss the threats of 
(re)enierging infectious diseases, the problem of 
antibiotic resistance, and the need for appropriate 
measures in Europe. The international character of the 
meeting, and the participation of experts from different 
disciplines, stressed the need for adequate international 
monitoring, prevention and therapeutic strategies based 
on fundamental clinical, epidemiologic and public- 
health research. 
Group A streptococci, pneumococci and stapliylo- 
cocci exeniplified old pathogens whose virulence and 
antibiotic resistance patterns have changed over the past 
decade, but new insights have been derived through 
molecular characterization of genes and clones. Joop 
Schellekens (Bilthoven, The Netherlands) illustrated 
how the incidence of severe group A streptococcal 
infections, after a steep decline until the 1970s, has 
increased again since 3 980 in several northwestern 
European countries and in the USA. Molecular 
epidemiologic data from a Dutch surveillance program 
provide evidence for the hypothesis that in The 
Netherlands this resurgence may be due to the clonal 
expansion of particular, more virulent, streptococcal 
strains. The emergence of multidrug resistance was 
described by Alexander Toniasz (New York, USA) as an 
‘accelerated evolution’ due to the selecting force of the 
introduction of large amounts of antimicrobial agents 
into the environment. This selective pressure leads to 
genetic recombinations and exchange of genetic deter- 
minants among microorganisms from various sources. 
The resulting new genotypes come at a biological price 
but may be evolutionarily very successful. Examples are 
niethicillin-resistant staphylococci that seem to have 
acquired the mecA gene from a Staphylococcus species 
from an animal source (where it is just a housekeeping 
gene) and niultidrug-resistant pneumococci. The price 
of antibiotic resistance is illustrated by the abnormal 
cell wall chemistry of resistant pneurnococci, while 
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evolutionary success is seen with both pneurnococci 
and staphylococci as the extensive geographic spread of 
resistant clones. 
The spread of niycobacterial infections in The 
Netherlands was tracked by molecular typing. Jan 
Van Enibden (Bilthoven, The Netherlands) illustrdted 
how this provides new insights into the epidemiology 
of transmission of niycobacterial infections among 
different ethnic groups, and presented evidence that 
isoniazid-resistant niycobacteria are transmitted less 
easily than streptomycin-resistant organisms. 
New opportunities for nosoconiial infections are 
created by changes in healthcare delivery systems, 
explained John McGowan Jr (Atlanta, USA). In the 
USA, recent changes have led to integrated health- 
care systems that aim at reduction of costs, resulting in 
reduction in staffing, and reuse of supplies and equip- 
ment. The first reports on outbreaks of infections due 
to these financial restraints are appearing. Integrated 
care also results in a blurring of the distinction between 
hospitals and community with respect to the prevalence 
of resistant strains and in the easy exchange of resistant 
strains among different institutions linked in one 
healthcare system. This exchange also occurs on  an 
international level, as international travel continues to 
increase. 
Movement of people greatly influences exposure 
to infection, but is not really a new phenomenon. Large 
migrations of people have occurred very often in history 
arid ‘one’s endemics became another’s epidemics’, 
stated Robert Feldman (London, UK). History also 
teaches that the influence of socio-economic factors on 
morbidity and niortality from infectious diseases was 
already known in the previous century. Unfortunately, 
environment, socio-economic status and lifestyle are 
difficult-to-control risk factors for infectious diseases. 
David Relnian (Palo Alto, USA) reviewed the 
molecular techniques that permit the recognition and 
amplification of hitherto cultivation-resistant micro- 
organisms. With the recognition of a pathogen, the 
road is opened to a better understanding of the 
pathogenesis of infection. For Bartoriella spp., for 
example, the host is a main deternlinant of the outconie 
of the infection, but the mode of transmission, the 
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vector and the presence ofbacterial virulence factors all 
influence the form of pathology that develops upon 
infection. The increasing availability of DNA or R N A  
sequencing methods and of sequence data will greatly 
influence the ability to identifj the microbial etiology 
of as yet unexplained illnesses. The second example of 
new insights through molecular techniques was given 
by Paul Griffiths (London, UK). He showed how the 
evolution of the characterization of new herpes viruses 
is driven by technical developments. The third example 
of the power of the new techniques was highlighted 
by the molecular analysis of the spread of HIV-1 in 
The Netherlands. Jaap Goudsmit (Amsterdam, The 
Netherlands) showed that the epidemic started in 1977 
among homosexual men and in 1980 among intra- 
venous drug users. Also, different phenotypes of the 
virus (syncytium-inducing and non-syncytium-in- 
ducing) are associated with different clinical outcomes. 
Finally, resistance in HIV develops easily: not only to 
zidovudine, but also to the new drugs that were 
registered €or use in The Netherlands in July 1996. 
Multidrug-resistant viruses were already observed. 
Chris Bartlett (London, UK) reviewed the ideal 
surveillance system and provided many exaniples where 
surveillance played an important role in recognizing 
new problems. International surveillance of com- 
municable diseases is needed in view of the increased 
population mobility and exchange of goods, the 
breakdown of communicable disease prevention in 
parts of eastern Europe and the re-emergence of both 
old and newly recognized infections. Initiatives on a 
European level have been taken, including a European 
training programme (EPIET), a surveillance bulletin 
(Eurosurveillance), and several disease-specific net- 
works. The new possibilities for fast communication 
provide the opportunity to create a ‘virtual’ center 
for disease control in Europe. The role of the public 
healthcare system in The Netherlands in the control 
of outbreaks of communicable diseases was illustrated 
by Anne Leentvaar-Kuijpers (Amsterdam, The Nether- 
lands). Jan Dute (Maastricht, The Netherlands) stressed 
that national and international aspects of surveillance 
and infectious disease legislation must comply with the 
prevailing international fundamental human rights. 
For the future, George Griffin (London, UK) stated 
that the new challenges lie in a better understanding of 
the host response to infection. We are starting to gain 
insight into the genetic polymorphism of cytokine 
responses and the central role of these molecules in the 
regulation of inflammation, but further investigation is 
needed. Research will also have to be directed towards 
epidemiology, infection control, diagnostics and new 
therapeutic strategies, added Rubin (Cambridge, USA). 
Henri Verbrugh (Rotterdam, The Netherlands) pro- 
posed an integrated service, the infectious disease 
service line, where infectious disease specialists, medical 
microbiologists and infection control ofticers collaborate 
to provide leadership and infectious disease manage- 
ment in institutions. The only way to survive with- 
out new antibiotics, concluded Jos van der Meer 
(Nijmegen, The Netherlands), is indeed by an integrated 
approach that includes a prudent use of antibiotics and 
well-organized infection control. 
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